Use of Enzyme Replacement Therapy (Laronidase) before Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis I: Experience in 18 Patients
We describe the use of enzyme replacement therapy in conjunction with hematopoietic stem cell transplantation in 18 consecutive patients with severe mucopolysaccharidosis type I. The survival and engraftment rate was 89% overall and 93% for the 15 patients who received full-intensity conditioning.
Abbreviations: ERT, Enzyme replacement therapy, GVHD, Graft-versus-host disease, HSCT, Hematopoietic stem cell transplantation, MPS I, Mucopolysaccharidosis type I
To access this article, please choose from the options below
Dr Wraith has undertaken paid and unpaid consultancy work for, and has been a principle investigator in, studies sponsored by Genzyme.
PII: S0022-3476(08)00577-5
doi:10.1016/j.jpeds.2008.07.004
© 2009 Mosby, Inc. All rights reserved.
